Caliber Therapeutics Overview

  • Status
  • Acquired/​Merged
  • Employees
  • 11
Employees
  • Latest Deal Type
  • M&A

Caliber Therapeutics General Information

Description

Developer of proprietary drug-delivery products designed to provide treatment for artherosclerotic diseases. The company's products include targeted angioplasty drug and are used for the treatment of vascular diseases to reduce thrombosis risk, as well as reduce the need to implant permanent devices, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Acquirer
Primary Office
  • 150 Union Square Drive
  • New Hope, PA 18938
  • United States
+1 (215) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Caliber Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-May-2018 000.00 Completed Generating Revenue
5. Later Stage VC 29-Sep-2017 0000 000.00 0000 Completed Generating Revenue
4. Later Stage VC (Series B) 15-Nov-2016 000 000.00 0000 Completed Generating Revenue
3. Early Stage VC (Series B) 30-Sep-2013 0000 000.00 0000 Completed Startup
2. Early Stage VC (Series A1) 27-Jul-2009 $8.25M $17.2M 0000 Completed Startup
1. Early Stage VC (Series A) 25-Aug-2008 $9M $9M 000.00 Completed Startup
To view Caliber Therapeutics’s complete valuation and funding history, request access »

Caliber Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A1 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Caliber Therapeutics’s complete cap table history, request access »

Caliber Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Hari Shankar Ph.D Vice President, Product Development
You’re viewing 1 of 8 executive team members. Get the full list »

Caliber Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Caliber Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Orchestra Medical Ventures Venture Capital Minority 000 0000 000000 0
Palisade Capital Management Hedge Fund Minority 000 0000 000000 0
To view Caliber Therapeutics’s complete investors history, request access »